I-Mab price target lowered to $7 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to move forward with a more focused strategy as a U.S.-based biotech, the analyst tells investors in a research note. The firm views I-Mab as “greatly underappreciated given the clinical promise of its assets.”